BE621398A - - Google Patents

Info

Publication number
BE621398A
BE621398A BE621398DA BE621398A BE 621398 A BE621398 A BE 621398A BE 621398D A BE621398D A BE 621398DA BE 621398 A BE621398 A BE 621398A
Authority
BE
Belgium
Prior art keywords
sugar
viruses
cores
candy
desc
Prior art date
Application number
Other languages
French (fr)
Publication date
Publication of BE621398A publication Critical patent/BE621398A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32661Methods of inactivation or attenuation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Description

       

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 



  "Vaccins antipoliomyé11tiques stables, &d!NiniatysT)3.ee par' voie buccale ". 



  La présente invention a pour objet des prépara- 
 EMI1.2 
 tiotté stables de virus de police élite, administrablea par voie buccale et obtenues à partir de virus de poliomyélite vivants atténués* 
Pour que les virus de poliomyélite puissent être 
 EMI1.3 
 administrés par voie buooalef il faut qu'ils soient s1iabla'i 

 <Desc/Clms Page number 2> 

      
 EMI2.1 
 Oit e. etBHy plusieurs :4'é! pour les .satire sous une forma ateble. L'ute 'ellsa oçsiaie t les :'r:r der des capsules Ce çtociâé eat oeút trîs* coliquJ et deT-de beaucoup de t.. B6 plus, beaucoup de patienta, surtout les enfants, n'ai-" r.%;Ut fèakj les capsules. ûr:.8 autre .: Fta peur mettre les j,3ü.s. OY2'.

   SOUS ur4e f&r't!8 stable eau de :eu aé larder avec du sucre at d'efi faire un sirop ou as leur donner lia fcrse de bonbons (voir brevet aué- s*icain  * 2.966,443, du 22 juin 1959  odemy o Médical Science ouf the U53Rf IriSt. foi PQ11omyJliU8 R:s:r:, Moscow, I960, Report ri-9 2(3l riéG 1959) paes Ó6, 72, 73). Le sirop de sucre administré par vois -buccale a lfinconv4rìent de ne pas être expo- 
 EMI2.2 
 teasnt dosable. ue plus, dans le uircp de sucre ainsi que dans les bonbons, les poliovirua ne sont stables à la température ambiante que quelques jours.

   Une autre   méthode   pour mettre une 
 EMI2.3 
 suspension de poliov.z^rzs dans une foi-tue stable, administrable pur voie 'buccale, serait la lyophilisation, mais elle n'est pas praticable parce qu'elle détruit l'i-afectiositê des virus- Pour cette raison, il était jusqu'à présent nécessaire, pour employer de tels vaccina, de les   congeler,   de les transporter dans cet 
 EMI2.4 
 état de les dégeler idiete.srzt avant l'emploie Or, la demanderesse a trouvé que l'on peut faire de man ere simple, des préparations de poliovirua administra- bles par voie buccale, en déposant des virus de poliomyélite sur un véhicule pharmaceutique solide, toléré par voie orale, 
 EMI2.5 
 de prd±4rence des noyaux de bonbona de sucre, et en séchant les noyaux ainsi traités dans des conditions stériles. 



   Pour préparer   le/présent     vaccin.,   on applique une suspension aqueuse de virus de poliomyélite de la souche Sabin, 
 EMI2.6 
 type le d'une MI 50 de 107'8-35t sur des noyaux de bonbons de sucre et on les y sèche, de pxé;'reno dans des conditions sté- riles. Pour accélérer le séchage, on peut utiliser une pression 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 réduite ou un courant de gaz stérilisa par exemple de¯ l'air. Le séchage peut être effectué à une température comprise entre 0 
 EMI3.2 
 et 3700, de préférence entre 20 et 370C.

   On détermine leu titreu 
 EMI3.3 
 de manière connue dans des cultures sur tissus, 
 EMI3.4 
 Si l'on désire que les virus de poliomyélite cit.-46- nues n'entrent pas en contact aven le milieu eutriquelfn-roi3ou- vre les noyaux de bonbons de sucre, sur lesquels les virus do poliomyélite sont déposes, d'une couche résistant au sac saotrique mais soluble dans l'intestin* Une telle couche ae laisse &ppli" quer par des méthodes galéniques usuelles, à deu températures comprisse entre 0 et 37 0, de préférence 20 et 3-7*0, lesquelles. n'atfeot0nt plia les polioviru8{voir Die pharmazeutisol) .InatjE'it" 
 EMI3.5 
 volume 14(1952), pages 183 et suivantes; Retainglonte lïaetipa ; cf Pharaaey  1961  Chapitre 37 01.',*oa,ting of Cablet8y Capeules 
 EMI3.6 
 and pages 476 et suivantes). 
 EMI3.7 
 



  Les polioyaoclna rdrs;.nit..1 pay vele b.lCet3.â =, qui font t3ae du présent brevet op4ol&]., se ;i3a'iunti par 
 EMI3.8 
 une fconna stabilité. Cornue il a été dit plus haut, l<ts rG,.sii"l.il,' - à l'état Ron-.lyopMlisë, ne eont stabisa 1& tapya'tre ambiante 
 EMI3.9 
 
 EMI3.10 
 que quelques jours, foinàis Que les IJr:pa.:ra.t.ion3. de v11'ull dt P011Q 
 EMI3.11 
 myélite conformes au présent brevet peuvent êt?<! at&9:<'s  4X . serines la température ambiante sans que leur v.,ïro. e pâtiaae sensiblement.

   Cette propriété constitue un grg.nd avant*- ge pour un lar;e e'aploi des vaccins contenant ï3e paL3.oYi,i vif 
 EMI3.12 
 vanta 
 EMI3.13 
 Les exemples ei-après décrivent la priparatiea des vaccins ain.ipoUosyé.t.i't;iqu9a avec des noy,4tix do 7azb 44 sucre coaae véhicule, sur le. surce desquels les poliovirua vivants atténués du ;¯7e 1, Il ou Ill, ou un .,aélqnge de ces trois cont dé,,,o,3éo puis aéoaûs. Chaque noyau de bonbons de sucre eat t5.u.Rl d'une co'iche G'C:ï'T. 3,t'c'fi j..f; dtYS3 nécessaire .pour infecter ar.a per3oxme, c' aG---d9.r environ 20C.COC & 500.000 50* 

 <Desc/Clms Page number 4> 

 
 EMI4.1 
 (DICT50 0 TOID50a Tis3ue Culture Infections Doae50) . 
 EMI4.2 
 



  Si l'en veut produire des vaccins que l'on désire stocker pour une période prolongée, on peut aussi déposer sur 
 EMI4.3 
 lua noyaux des bonbons de sucre une dose de poliovîrue plus dje- vde, par exemple une dose plusieurs fois plus forte que colle 
 EMI4.4 
 requise pour 1'infection, d'une seule personne. On peut ainsi 
 EMI4.5 
 préparer des préparations dites "c&ulti-dosea*1 qui contiennent, pur exeavde  50 ou 100 fois la D:tC50 mon-ciomièe plus haut.

   Na- - .turelleaent, on doit diluer ces prépamtiona avant l'emploi, qu'elles sont destinées à être administrées à un nombre ## de personnes d'autant plus grand, par exemple 50 ou 100 peraon- nat!..' Indépendamment des noyuux de bonbons de auore, on. pe... t U.UB., i u1:iliE!er OOtll:;.8 vâ"n10111e solide, d'autres substances toléra par voie orale. par exemple des noyaux de gélatine. ces Ion noyaux do bobonn do et4c" ont 1  avantage qu'il  et dissolvent i'Is rpid6!aent dana la bouche* t Avec les poliovirus vivait  atténuas de Sabin, types 1, il et III, il est possible u..',ü aa des v;.icc1u:3 t1"iv:::.lents pour voie orale. Les vaccins tnv.)l6nt8 pre,arès à partir de ces trois 'types de pcUov1rua auvent aaaai dtre eonaervés pendant plus dqeix se... t1:lM lu température asbiante. 
 EMI4.6 
 



  Les exemples suivante illustrent l'invention 
 EMI4.7 
 aai.8 eu liEdier 1h portée. fe/alIg, l, Ot ru*ouvru chacun des 50v coyaux de bonbons tilt &.\1I!rt){li1.(.bu.l1 t3cch."'ri. d'un due 8 ew) en appliquant tcuitçô u, tcuttei ft, 0 à-t¯a ur. L.sllon tcrtiunt, 20 e&"' d'un #,. i.Á4\tI.%O cï.e:.;t:*t 1 rrtje dl 1,.1:">;:

   S""$'\;!:':';;' on. aqueuse de foliovi1"' te.çe 5(3-ibiJi} uee tt-.o IC.7.5 5  * l j.az-tiua d'URS sc-lu* tie 4.e 6:J.;.r (i çrtiao de- 3.:crc cr piriie d'eu); en seen l s yux *CeC ïi lf<ixaô dn ccurr.r.t, a* air jt,vrilis*4 et'on les %uxit --.U:Rc --Cac4èe r&ectriae tnvcro-3clu.ble. 

 <Desc/Clms Page number 5> 

 
 EMI5.1 
 tr.-.it-iï3 dOn -après rite-nt : lO5 'vîl?Brfi *   &>5.0CO -c-iprèa UI. stockée de six saa-Inas 1'/>' .}15Dl,O 2j7..\X() Le poliûv.ocin uàainiatruble -'îï' vei > liuoo ,1  Ainai 1,r1.'n.r"; '.au.'t dtre Tcok ' pendant six se.naa .1 tas" Pv:ratu3'â aalji'inw .:iï. psï'tô a'uotivit.', c tus 1  des erreurj aes essuie* Cn pr-Ji'ure a va.ecis le virua ds 'Joliomyli;e à partir de poliovirus du type II(J-bin) d'une DIgQ de bzz selcn 1 méthode décrite âuna l'exe-1 Lt-ti titres ;le.; ao;

   j,ux ce 'bonbon:! de D1.l0rQ iï.ai 
 EMI5.2 
 truites sont 
 EMI5.3 
 -après le tr<d;e,118u>: l05t286DI;o   193,0iO -après un stockage de 6 semaines 105,354DI50 III 225*000 Un stockage de six semaines à 2090 ne change 
 EMI5.4 
 pratiquement pas l'activité de cette préparation. 
 EMI5.5 
 



  .t:.i#IJPIE On fait des prlfr-uru tions de virus de pol101IlY- lite à partir de poliovirua du type 111( Sabin) dont la -DI50 est 107 t 714. 



  Les titres des BOy.;lX de boutons de sucres o.iriS1 traites santi - après le traitement : lo5J68I50 484tOOQ -après un stockage de R Ai 7 6 semaines 10 ,417DI,O . 261..000 
 EMI5.6 
 Les titres daterai nia aontrent !utapr&a lu stooitu.*- 
 EMI5.7 
 ge l'activité de la préparation 'este d'tus li marce d'erreur des eaaio* 
 EMI5.8 
 EXEMPLE 4: 
 EMI5.9 
 On mélange en:3e::t"b13 20 cm de poliov1raQ type 1 (Sabin) dont la ?i ost 10 ' ,20 cm 3 de poliovirus tye Il 

 <Desc/Clms Page number 6> 

 
 EMI6.1 
 .i3:x:, dont 1* m,5Q est 101,5'0 et 20 #3 da pcl1cv1rua type: III(3abin) dtnt It 150 est 107.444, et on trvi11e.ce mélange ##105 'Xft méthods âêcrits dans Ilézemple 1 peur faire des prépa- rat1PnB virde de pol10J&lit6. 



  Leu titres de noyaux des bçnbor.9 de saers ft.1ns1 
 EMI6.2 
 traités sont$ 
 EMI6.3 
 ;r6. le titeen : t lo5t80r50 . 381*000 <'IIi{i.,Pris un stockage de 5 "'llL 373,*moco 6 8ft::\.':L1nea 10 f jJ!50 JO:: 373<OCO . Il res8(.r1o de ces onlfi'yes que la préparation ottxx: lea virus des types I, II et III peut être stocke pendant nix sea1nes sana perdre son activité. 



  X E S 9 fi: 
 EMI6.4 
 101 33ee vacoîns:antipoliomyélîtîquee administrableal 
 EMI6.5 
 par vole buccale, contenant des virus de poliomyélite vivants et 
 EMI6.6 
 atténuée, ot un véhicule pharmaceutique solide, toléré par voie orale, de prèïérenoo des noyaux de bonbons de sucre, les virus 
 EMI6.7 
 étant des virus de poliomyélite de la souche Satin, types I, 
 EMI6.8 
 21 ou 112, eu. un mélange de ces types, vivants* atténuéa, en quantité de 200.000 à 5.00.000 Dra#50. 



  20) Des variétés des vaccins spécifiés sous 10), présentant lis particularités suivantes, prisas séparément ou . en aom inniso%1r a) le véhicule phamaoautique est un noyau de 
 EMI6.9 
 'bonbon de sucre* b) le véhicule sur lequel les virus de poliomyélite 
 EMI6.10 
 aont déposé. est muni d'une couche entéroeoluble. 

**ATTENTION** fin du champ DESC peut contenir debut de CLMS **.



   <Desc / Clms Page number 1>
 
 EMI1.1
 



  "Stable polio vaccines, & d! NiniatysT) 3.ee by the oral route".



  The present invention relates to preparations
 EMI1.2
 elite police virus stable, oral administered and obtained from live attenuated poliomyelitis virus *
So that polio viruses can be
 EMI1.3
 administered by the buooalef route, they must be s1iabla'i

 <Desc / Clms Page number 2>

      
 EMI2.1
 Oit e. etBHy several: 4'é! for .satire them in a suitable form. The ute 'ellsa oçsiaie t the:' r: der capsules This association is very * colic and deT-deT-deT a lot of t .. B6 plus, a lot of patienta, especially the children, did not. %; Ut fèakj the capsules. Ûr: .8 other.: Fta can put the j, 3ü.s. OY2 '.

   UNDER ur4e f & r't! 8 stable water of: had to lard with sugar and to make a syrup or to give them the fcrse of candies (see US patent * 2,966,443, of June 22, 1959 odemy o Medical Science ouf the U53Rf IriSt. faith PQ11omyJliU8 R: s: r :, Moscow, I960, Report ri-9 2 (3l riéG 1959) paes Ó6, 72, 73). The sugar syrup administered by your mouth should not be exposed to
 EMI2.2
 dosable teasnt. Moreover, in sugar uircp as well as in candies, polioviruses are only stable at room temperature for a few days.

   Another method to put a
 EMI2.3
 suspension of poliov.z ^ rzs in a stable faith, administrable purely orally, would be lyophilization, but it is not practicable because it destroys the infectiousness of viruses. For this reason, it was until now necessary, in order to use such vaccina, to freeze them, to transport them in this
 EMI2.4
 state of thawing them idiete.srzt before use Now, the applicant has found that it is possible to make in a simple manner, preparations of poliovirua administered by the oral route, by depositing poliomyelitis viruses on a solid pharmaceutical vehicle , tolerated orally,
 EMI2.5
 preferably from the cores of sugar candy, and drying the cores thus treated under sterile conditions.



   To prepare the present vaccine, an aqueous suspension of poliomyelitis virus of the Sabin strain is applied,
 EMI2.6
 Type 1e of a 1078-35t MI 50 on candy cores and dried therein, by weight, under sterile conditions. To speed up drying, you can use pressure

 <Desc / Clms Page number 3>

 
 EMI3.1
 reduced or a stream of gas sterilized, for example, air. Drying can be carried out at a temperature between 0
 EMI3.2
 and 3700, preferably between 20 and 370C.

   We determine their titreu
 EMI3.3
 in a known manner in tissue cultures,
 EMI3.4
 If it is desired that the poliomyelitis viruses cit.-46- nues do not come into contact with the eutric medium, then open the nuclei of sugar candies, on which the poliomyelitis viruses are deposited, with a layer resistant to the saotric sac but soluble in the intestine * Such a layer is allowed to spread by usual galenic methods, at two temperatures between 0 and 37 ° C., preferably 20 and 3-7 ° C., which do not reach folded the polioviru8 (see Die pharmazeutisol) .InatjE'it "
 EMI3.5
 volume 14 (1952), pages 183 and following; Retainglonte lïaetipa; cf Pharaaey 1961 Chapter 37 01. ', * oa, ting of Cablet8y Capeules
 EMI3.6
 and pages 476 and following).
 EMI3.7
 



  The polioyaoclna rdrs; .nit..1 pay vele b.lCet3.â =, which make t3ae of the present patent op4ol &]., Se; i3a'iunti by
 EMI3.8
 a fconna stability. Retorted it was said above, l <ts rG, .sii "l.il, '- in the state Ron-.lyopMlisë, did not stabilize 1 & tapya'tre ambient
 EMI3.9
 
 EMI3.10
 that a few days, hay that the IJr: pa.: ra.t.ion3. from v11'ull dt P011Q
 EMI3.11
 myelitis according to the present patent may be? <! at & 9: <'s 4X. serines at room temperature without their v., ïro. e patiaae noticeably.

   This property constitutes a front grg.nd * - age for a lar; e 'use of vaccines containing ï3e paL3.oYi, i vive
 EMI3.12
 boasted
 EMI3.13
 The following examples describe the priparatiea of the ain.ipoUosyé.t.i't; iqu9a vaccines with nuclei, 4tix do 7azb 44 sugar coaae vehicle, on the. on which the living attenuated polioviruses of; ¯7e 1, II or Ill, or one., aelqnge of these three count,, o, 3o, then aeoaûs. Each kernel of sugar candy eat t5.u.Rl of a G'C: ï'T co'iche. 3, t'c'fi j..f; dtYS3 needed. to infect ar.a per3oxme, c 'aG --- d9.r around 20C.COC & 500,000 50 *

 <Desc / Clms Page number 4>

 
 EMI4.1
 (DICT50 0 TOID50a Tis3ue Culture Infections Doae50).
 EMI4.2
 



  If you want to produce vaccines that you want to store for an extended period, you can also drop on
 EMI4.3
 the cores of sugar candies a dose of polio more dje- vde, for example a dose several times stronger than glue
 EMI4.4
 required for infection from one person. We can thus
 EMI4.5
 Prepare so-called "c & ulti-dosea * 1 preparations which contain, pure exeavde 50 or 100 times the D: tC50 mentioned above.

   Naturally, these prepamtiona must be diluted before use, that they are intended to be administered to an even greater number ## of people, for example 50 or 100 peraon- nat! .. 'Independently auore candy cores, on. pe ... t U.UB., i u1: iliE! er OOtll:;. 8 vâ "n10111e solid, other substances tolerated orally. for example gelatin cores. these Ion cores do bobonn do et4c" have 1 advantage that it and dissolve i'is rpid6! aent in the mouth * t With the attenuated polioviruses of Sabin, types 1, il and III, it is possible u .. ', ü aa of v; .icc1u: 3 t1 "iv :::. Slow for oral use. Tnv vaccines.) L6nt8 pre, arès from these three types of pcUov1rua awning aaaai to be kept for more than six ... t1: lM read asbiant temperature.
 EMI4.6
 



  The following examples illustrate the invention
 EMI4.7
 aai.8 had liEdier 1h scope. fe / alIg, l, Ot ru * opened each of the 50v tilt candy cores &. \ 1I! rt) {li1. (. bu.l1 t3cch. "'ri. of a due 8 ew) by applying tcuitçô u, tcuttei ft, 0 to-t¯a ur. L.sllon tcrtiunt, 20 th & "'a # ,. i.Á4 \ tI.% O cï.e:.; t: * t 1 rrtje dl 1, .1: "> ;:

   S "" $ '\;!:': ';;' we. watery of foliovi1 "'te.çe 5 (3-ibiJi} uee tt-.o IC.7.5 5 * l j.az-tiua of URS sc-lu * tie 4.e 6: J.;. r (i çrtiao de- 3.:crc cr piriie d'eu); in seen ls yux * CeC ïi lf <ixaô dn ccurr.rt, a * air jt, vrilis * 4 and on% uxit -. U: Rc - -Cac4èe r & ectriae tnvcro-3clu.ble.

 <Desc / Clms Page number 5>

 
 EMI5.1
 tr .-. it-iï3 dOn -after rite-nt: lO5 'vîl? Brfi * &> 5.0CO -c-iprèa UI. stored from six saa-Inas 1 '/>'.} 15Dl, O 2j7 .. \ X () The poliûv.ocin uàainiatruble -'îï 'vei> liuoo, 1 Ainai 1, r1.'nr ";' .au. 't d be Tcok' for six se.naa .1 pile "Pv: ratu3'â aalji'inw.: iï. psï'tô a'uotivit. ', c tus 1 of the errors i wiped * Cn pr-Ji'ure a va.ecis the virua ds' Joliomyli; e from poliovirus type II (J-bin) of a DIgQ of bzz selcn 1 method described âuna the exe-1 Lt-ti titles; the .; ao;

   j, ux this' candy :! by D1.l0rQ iï.ai
 EMI5.2
 trout are
 EMI5.3
 -after the tr <d; e, 118u>: l05t286DI; o 193.0iO -after a 6 week storage 105.354DI50 III 225 * 000 A six week storage at 2090 does not change
 EMI5.4
 practically no activity of this preparation.
 EMI5.5
 



  .t: .i # IJPIE Pol101IlYlitis virus predictions were made from poliovirus type 111 (Sabin) whose -DI50 was 107 to 714.



  Titles of BOy.; LX of o.iriS1 sugar buttons treated health - after treatment: lo5J68I50 484tOOQ - after storage of R Ai 7 6 weeks 10, 417DI, O. 261..000
 EMI5.6
 The titles will date nia aontrent! Utapr & a lu stooitu. * -
 EMI5.7
 ge the activity of the preparation is free of error from the eaaio *
 EMI5.8
 EXAMPLE 4:
 EMI5.9
 One mixes in: 3e :: t "b13 20 cm of poliov1raQ type 1 (Sabin) of which the? I ost 10 ', 20 cm 3 of poliovirus tye II

 <Desc / Clms Page number 6>

 
 EMI6.1
 .i3: x :, of which 1 * m, 5Q is 101,5'0 and 20 # 3 da pcl1cv1rua type: III (3abin) dtnt It 150 is 107.444, and we trvi11e.this mixture ## 105 'Xft methods written in Ilézemple 1 can make prepa- rat1PnB virde de pol10J & lit6.



  Leu nuclei titles of saers bçnbor.9 ft.1ns1
 EMI6.2
 processed are $
 EMI6.3
 ; r6. the titeen: t lo5t80r50. 381 * 000 <'IIi {i., Took a storage of 5 "' llL 373, * moco 6 8ft :: \. ': L1nea 10 f jJ! 50 JO :: 373 <OCO. It res8 (.r1o of these Onlfi'yes that the preparation ottxx: virus types I, II and III can be stored for nix weeks without losing its activity.



  X E S 9 fi:
 EMI6.4
 101 33ee vacoîns: anti-polio administrableal
 EMI6.5
 by mouth, containing live poliomyelitis viruses and
 EMI6.6
 attenuated, ot a strong, orally tolerated, pharmaceutical carrier of pre-release of candy kernels, viruses
 EMI6.7
 being Polio viruses of the Satin strain, types I,
 EMI6.8
 21 or 112, eu. a mixture of these types, living * attenuated, in amounts of 200,000 to 5.00,000 Dra # 50.



  20) Varieties of the vaccines specified under 10), exhibiting the following peculiarities, taken separately or. in aom inniso% 1r a) the phamaoautic vehicle is a nucleus of
 EMI6.9
 'sugar candy * b) the vehicle on which the polio viruses
 EMI6.10
 have filed. is provided with an entero-soluble layer.

** ATTENTION ** end of DESC field can contain start of CLMS **.


    
BE621398D BE621398A (en)

Publications (1)

Publication Number Publication Date
BE621398A true BE621398A (en) 1900-01-01

Family

ID=194439

Family Applications (1)

Application Number Title Priority Date Filing Date
BE621398D BE621398A (en)

Country Status (1)

Country Link
BE (1) BE621398A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420785A2 (en) * 1989-09-29 1991-04-03 The Nisshin Oil Mills, Ltd. Stable immunogen composition
EP0603992A1 (en) * 1992-12-22 1994-06-29 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420785A2 (en) * 1989-09-29 1991-04-03 The Nisshin Oil Mills, Ltd. Stable immunogen composition
EP0420785A3 (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition
US5176909A (en) * 1989-09-29 1993-01-05 The Nisshin Oil Mills, Ltd. Stable immunogen composition for oral administration
US5591433A (en) * 1991-06-21 1997-01-07 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
EP0603992A1 (en) * 1992-12-22 1994-06-29 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
EP0603992B1 (en) * 1992-12-22 1996-10-09 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Similar Documents

Publication Publication Date Title
CA2986915C (en) Microbiota restoration therapy (mrt) compositions and methods of manufacture
US11654164B2 (en) Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) Microbiota restoration therapy (MRT) compositions and methods of manufacture
NO142866B (en) NEW BENZODIAZEPINE DERIVATIVES FOR USE AS PREPARING MATERIAL AND PROCEDURES IN PRODUCING THEREOF
JPS58113124A (en) Solid formed article
MX2008014398A (en) Nicotine-carrier vaccine formulation.
US10799539B2 (en) Microbiota restoration therapy (MRT) compositions and methods of manufacture
BE621398A (en)
CN114053343A (en) Traditional Chinese medicine composition, preparation method and application
Zain et al. Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards
ES2314772T3 (en) COMPOSITION FOR THE PREVENTION AND TREATMENT OF CATARRAL AFFECTIONS.
Pardeshi et al. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review
RU2225709C2 (en) Lyophilizate with improved reproducibility to parent state (variants), method for its preparing and pharmaceutical preparation
TWI684451B (en) Silybin injection and its preparation method
CN107011419A (en) Active glycopeptide of Radix Isatidis with antiviral activity and preparation method and application
BE1005589A3 (en) MEDICAMENT FOR THE TREATMENT OF DERMATITIS.
KR102540346B1 (en) Composition for attracting honeybees and drug delivery system for beekeeping comprising the same
CN105997868B (en) A kind of dabigatran etcxilate nanometer mixed micelle and preparation method thereof
FR2479690A1 (en) USEFUL MEDICINE, IN PARTICULAR FOR THE TREATMENT OF ARTHRITIS AND ITS PROCESS FOR OBTAINING EXTRACTION OF LEAVES AND RHIZOMES OF POLYPODIACEAE
CN107998111A (en) Applications of the DAS in the acute immune liver injury medicament for preparing prevention/or treatment LPS/D-GalN inductions
CN113288943A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing coronavirus infection
WO2020143333A1 (en) Use of taraxasterol for preparing drug for preventing and treating alzheimer&#39;s disease
Kumar et al. Solid dispersion techniques: a review
KR101731065B1 (en) Method for preparing novel extract of salicornia herbacea having improved anti-diabetic efficacy and toxicity, and composition comprising the extract of salicornia herbacea
CN108042551A (en) A kind of purposes of composition in treatment of viral myocarditis drug is prepared